Pharmacokinetics Study of Antitumor B in Healthy Volunteers

Healthy Adults Clinical Trial

Official title:

Pharmacokinetics Study of Antitumor B in Healthy Volunteers

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT04230057
• Other study ID #: STUDY00001235
• Status: Active, not recruiting
• Start date: December 12, 2019
• Est. completion date: August 30, 2021

Study information

• Verified date: November 2020
• Source: University of Houston
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The purpose of this study is to evaluate the single-dose oral pharmacokinetics of an herbal supplement - Antitumor B - in healthy subjects.

Description:

Antitumor B (ATB), also known as Zeng Sheng Ping, is a Chinese herbal mixture composed of six plants: Sophora tonkinensis, Polygonum bistorta, Prunella vulgaris, Sonchus brachyotus, Dictamnus dasycarpus, and Dioscorea bulbifera. ATB is available as 300 mg tablets and has been traditionally used in China for dysplasia (dose 4-8 tables/ twice daily). Several studies in rodents and humans have been published demonstrating the chemopreventive activity of ATB against various cancers (e.g. lung, esophageal and oral). However, the investigators currently do not know what pharmacologically relevant concentration levels can be achieved systemically for different components of ATB in humans. Since it is a complex herbal mixture containing various key active components (KACs), relative levels of KACs in the ATB mixture can influence the bioavailability and pharmacokinetic of the individual KACs. The proposed study aim to estimate the plasma concentration of four key active components in a tablet with a chemical-defined ATB mixture. The investigators are interested in doing a human single-dose (8 tablets once) full pharmacokinetic study of ATB tablets. The investigators plan to collect 9 blood and 9 saliva samples from 8 healthy volunteers over a period of 24 hours (at pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours) to

1. determine the saliva and plasma concentration of four key constituents of ATB (matrine, dictamnine, maackiain, fraxinellone) and

2. develop the in vivo correlation between plasma and saliva concentrations

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 12
• Est. completion date: August 30, 2021
• Est. primary completion date: January 21, 2020
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• A potential subject must meet all the following inclusion criteria to be eligible to participate in the study.

1. Health questionnaire filled on the day of recruitment, after signing the written consent form

2. Participants must receive administration of study agent within 21-28 calendar days of being selected as subject after screening procedure is completed

3. Healthy male or female subjects aged =18 and =40 years of age

4. Subjects must have a body mass index (BMI) between 18.0-29.9 kg/m² inclusive

5. CBC/differential obtained within 14 calendar days prior to selection as subject for drug administration , with adequate bone marrow function defined as follows: Absolute neutrophil count (ANC) = 1,500 cells/mm3; Platelets = 100,000 cells/mm3; Hemoglobin = 8.0 g/dl (Note: The use of transfusion or other intervention to achieve Hgb

= 8.0 g/dl is acceptable.);

6. Adequate renal and hepatic function within 14 calendar days prior to selection as subject for drug administration defined as follows: Serum creatinine < 1.5 mg/dl or creatinine clearance (CCr) = 50 ml/min within 14 calendar days prior to selection as subject for drug administration, determined by 24-hour collection or estimated by Cockcroft-Gault formula: CCr male = [(140 - age) x (wt in kg)] [(Serum Cr mg/dl) x (72)] CCr female = 0.85 x (CrCl male)

7. Total bilirubin < 2 x the institutional Upper limit of Normal range (ULN) within 14 calendar days prior to selection as subject for drug administration

8. AST or ALT = 3 x the institutional ULN within 14 calendar days prior to selection as subject for drug administration

9. ALP or GGT = 2.5 x the institutional ULN within 14 calendar days prior to selection as subject for drug administration

10. Magnesium, calcium, glucose, potassium, and sodium within 14 calendar days prior to selection as subject for drug administration, with the following required parameters: Magnesium: > 0.9 mg/dl or < 3 mg/dl; Calcium: > 7 mg/dl or < 12.5 mg/dl; Glucose: > 40 mg/dl or < 250 mg/dl; Potassium: > 3 mmol/L or < 6 mmol/L; Sodium: > 130 mmol/L or < 155 mmol/L.

11. Participant must have active health insurance coverage at the time of study

12. Participants must be able to understand study-specific information and instructions in English.

13. Participant must be willing to fully comply with study procedures and restrictions.

14. Participant must be able to provide written, personally signed, and dated informed consent to participate in the study, in accordance with the ICH Good Clinical Practice (GCP) Guideline E6 (1996) and applicable regulations, before completing any studyrelated procedures

Exclusion Criteria:

1. History of active liver disease or cancer.

2. Severe current or recurrent comorbidity such as (e.g., cardiovascular, haematological, neurological, endocrine, renal, liver, GI, HIV-AIDS, or other conditions such as cancer) that could affect the absorption and/or disposition of ATB

3. Any disease/illness diagnosed by a licensed physician.

4. Blood report positive for HIV and/or Hepatitis B and C tests

5. Has had an acute illness within two weeks prior to screening.

6. Pregnant or lactating women are ineligible due to unforeseeable risks to embryo or fetus.

7. Concurrent use of any prescription medication (including medicinal botanical) except birth control pills, over the counter medication and supplements except Vitamins and mineral supplements, or herbal supplements in form of herbal mixtures, teas or individual compounds (such as querctein, curcumin, echinacea, flaxseed, ginseng, ginkgo, soy etc.) that the study PI believes could potentially impact the results/objectives of this study.

8. Concurrent use of recreational drugs or alcohol during the study (self-declared by study participants)

9. Prisoners

10. Economically and/or educationally disadvantaged persons

Related Conditions & MeSH terms

• Healthy Adults

Intervention

Dietary Supplement:
• Antitumor B
Single dose 2400 mg

Locations

Country	Name	City	State
United States	University of Houston, College of Pharmacy	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
University of Houston

Country where clinical trial is conducted

United States, 

References & Publications (9)

Gao S, Yang Z, Yin T, You M, Hu M. Validated LC-MS/MS method for the determination of maackiain and its sulfate and glucuronide in blood: application to pharmacokinetic and disposition studies. J Pharm Biomed Anal. 2011 May 15;55(2):288-93. doi: 10.1016/j.jpba.2011.01.015. Epub 2011 Jan 22. — View Citation

Lin P, Zhang J, Rong Z, Han R, Xu S, Gao R, Ding Z, Wang J, Feng H, Cao S. Studies on medicamentous inhibitory therapy for esophageal precancerous lesions--3- and 5-year inhibitory effects of antitumor-B, retinamide and riboflavin. Proc Chin Acad Med Sci Peking Union Med Coll. 1990;5(3):121-9. — View Citation

Lin P. [Medicamentous inhibitory therapy of precancerous lesions of the esophagus--3 and 5 year inhibitory effect of antitumor B, retinamide and riboflavin]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 1990 Aug;12(4):235-45. Chinese. — View Citation

Lin PZ, Zhang JS, Cao SG, Rong ZP, Gao RQ, Han R, Shu SP. [Secondary prevention of esophageal cancer--intervention on precancerous lesions of the esophagus]. Zhonghua Zhong Liu Za Zhi. 1988 May;10(3):161-6. Chinese. — View Citation

Sun Z, Guan X, Li N, Liu X, Chen X. Chemoprevention of oral cancer in animal models, and effect on leukoplakias in human patients with ZengShengPing, a mixture of medicinal herbs. Oral Oncol. 2010 Feb;46(2):105-10. doi: 10.1016/j.oraloncology.2009.06.004. Epub 2009 Dec 21. — View Citation

Wang Y, Yao R, Gao S, Wen W, Du Y, Szabo E, Hu M, Lubet RA, You M. Chemopreventive effect of a mixture of Chinese Herbs (antitumor B) on chemically induced oral carcinogenesis. Mol Carcinog. 2013 Jan;52(1):49-56. doi: 10.1002/mc.20877. Epub 2011 Nov 15. — View Citation

Yang Z, Gao S, Yin T, Kulkarni KH, Teng Y, You M, Hu M. Biopharmaceutical and pharmacokinetic characterization of matrine as determined by a sensitive and robust UPLC-MS/MS method. J Pharm Biomed Anal. 2010 Apr 6;51(5):1120-7. doi: 10.1016/j.jpba.2009.11.020. Epub 2009 Nov 26. — View Citation

Yin T, Yang G, Ma Y, Xu B, Hu M, You M, Gao S. Developing an activity and absorption-based quality control platform for Chinese traditional medicine: Application to Zeng-Sheng-Ping(Antitumor B). J Ethnopharmacol. 2015 Aug 22;172:195-201. doi: 10.1016/j.jep.2015.06.019. Epub 2015 Jun 20. — View Citation

Zhang Z, Wang Y, Yao R, Li J, Yan Y, La Regina M, Lemon WL, Grubbs CJ, Lubet RA, You M. Cancer chemopreventive activity of a mixture of Chinese herbs (antitumor B) in mouse lung tumor models. Oncogene. 2004 May 6;23(21):3841-50. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax of matrine, dictamnine, maackiain and fraxinellone in plasma	Maximum (peak) observed drug concentration in plasma	Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose
Primary	Cmax of matrine, dictamnine, maackiain and fraxinellone in saliva	Maximum (peak) observed drug concentration in saiva	Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose
Primary	Tmax of matrine, dictamnine, maackiain and fraxinellone in plasma	Time of Maximum (peak) observed drug concentration in plasma	Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose
Primary	Tmax of matrine, dictamnine, maackiain and fraxinellone in saliva	Time of Maximum (peak) observed drug concentration in saliva	Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose
Primary	AUC0-24 of matrine, dictamnine, maackiain and fraxinellone in plasma	Area under the curve of plasma concentration-time profile	Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose
Primary	AUC0-24 of matrine, dictamnine, maackiain and fraxinellone in saliva	Area under the curve of saliva concentration-time profile	Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose
Secondary	Plasma-saliva IVIVC	In vivo-in vivo correlation established between plasma and saliva concentrations	Pre-dose, 0.5, 1, 2, 3, 4, 6, 8, and 24 hours post dose

External Links

•   ACAPHA in Preventing Lung Cancer in Former Smokers With Bronchial Intraepithelial Neoplasia
•   Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 1 of 3
•   Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 2 of 3
•   Standardization and Clinical Testing of ACAPHA for Cancer Prevention Part 3 of 3